Adaptation of a previously validated vaccination report card for use in adult vaccine clinical trials to align with the 2007 FDA Toxicity Grading Scale Guidance

Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age

(2011) Joost N. Vermeulen et al.   VACCINE

Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old

(2010) Myron J Levin et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Sustained Efficacy of the Pentavalent Rotavirus Vaccine, RV5, up to 3.1 Years Following the Last Dose of Vaccine

(2010) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines

(2010) A. Arguedas et al.   VACCINE

Human Herpesvirus 8 DNA Load in the Leukocytes Correlates with the Platelet Counts in HIV Type 1-Infected Individuals

(2009) Rumi Minami et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older

(2009) S. C. Sutradhar et al.   Clinical and Vaccine Immunology

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

(2008) Frances H. Priddy et al.   CLINICAL INFECTIOUS DISEASES